471A Stock Overview
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
aTyr Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.43 |
| 52 Week High | US$2.38 |
| 52 Week Low | US$0.98 |
| Beta | 1.23 |
| 1 Month Change | -21.86% |
| 3 Month Change | -2.05% |
| 1 Year Change | -18.75% |
| 3 Year Change | -56.93% |
| 5 Year Change | -81.19% |
| Change since IPO | -96.16% |
Recent News & Updates
Recent updates
Shareholder Returns
| 471A | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.7% | 0.8% | 1.2% |
| 1Y | -18.8% | -24.4% | 2.0% |
Return vs Industry: 471A exceeded the German Biotechs industry which returned -24.4% over the past year.
Return vs Market: 471A underperformed the German Market which returned 2% over the past year.
Price Volatility
| 471A volatility | |
|---|---|
| 471A Average Weekly Movement | 11.9% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 471A's share price has been volatile over the past 3 months.
Volatility Over Time: 471A's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 58 | Sanjay Shukla | www.atyrpharma.com |
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders.
aTyr Pharma, Inc. Fundamentals Summary
| 471A fundamental statistics | |
|---|---|
| Market cap | €99.49m |
| Earnings (TTM) | -€47.00m |
| Revenue (TTM) | €329.24k |
307.9x
P/S Ratio-2.2x
P/E RatioIs 471A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 471A income statement (TTM) | |
|---|---|
| Revenue | US$353.00k |
| Cost of Revenue | US$42.29m |
| Gross Profit | -US$41.94m |
| Other Expenses | US$8.45m |
| Earnings | -US$50.39m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.74 |
| Gross Margin | -11,881.02% |
| Net Profit Margin | -14,274.50% |
| Debt/Equity Ratio | 0% |
How did 471A perform over the long term?
See historical performance and comparison